Cas:1176-08-5 Phenyltoloxamine citrate manufacturer & supplier

Chemical Name:Phenyltoloxamine citrate

CAS.NO:1176-08-5

Synonyms:Phenyltoloxamine citrate;Phenyltoloxamine citrate salt;2-(2-benzylphenoxy)-N,N-dimethylethanamine,2-hydroxypropane-1,2,3-tricarboxylic acid;MFCD00038875;EINECS 214-644-7

Molecular Formula:C₂₃H₂₉NO₈

Molecular Weight:447.47800

HS Code:2922509090

Physical and Chemical Properties:

Melting point:188-190 °C(lit.)

Boiling point:359.2ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:144.60000

Exact Mass:447.18900

LogP:1.96930

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Phenyltoloxamine citrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 214-644-7 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenyltoloxamine citrate Use and application,Phenyltoloxamine citrate salt technical grade,usp/ep/jp grade.

Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. Phenyltoloxamine citrate manufacturer CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch. Phenyltoloxamine citrate supplier Also, states with higher obesity rates also tend to have higher rates of food insecurity, which means lower incomes in general,” she noted. “Bariatric surgery is an expensive proposition, especially if one does not have good insurance coverage for it. Phenyltoloxamine citrate vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. Phenyltoloxamine citrate factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.